New AI-powered algorithm delivers more personalized birth control by adapting to individual cycle patterns while maintaining established effectiveness rates
Danaher’s (NYSE:DHR) Masimo unit announced today that it received FDA 510(k) clearance for its Patient State Index (PSi) for pediatric patients.
INDIANAPOLIS, July 24, 2026 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and Candida vaginitis (CV) from a single vaginal swab sample. It enables accurate and timely results that can lead to improved patient outcomes and enhanced healthcare efficiencies.
A machine learning tool that analyzes information already captured in a child’s electronic health record helped pediatricians more accurately assess asthma risk in standardized clinical case scenarios, according to a pilot randomized clinical trial led by a Regenstrief Institute researcher.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, new University of Virginia Comprehensive Cancer Center research reveals. The findings could open the door to new ways to prevent breast cancer metastasis (spread), improve patient outcomes and save lives.
Claria Medical announced today that it received FDA de novo authorization for its Claria system for minimally invasive hysterectomies.
Fertility declines as women get older for many reasons, such as a drop in egg quality, decreased follicle numbers and hardening of ovarian tissues.
Researchers have solved a long-standing mystery of how abnormal chromosomes drive cancer, identifying 81 new genes involved in aggressive breast cancer.
Carea, the pregnancy and postnatal wellbeing app, has launched its new Contraction Timer designed to support women during labour through a combination of contraction tracking, labour pattern analysis and wellbeing tools.
Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool – the first in Europe and the United Kingdom to detect breast cancer using magnetic resonance imaging – which automatically identifies suspected lesions on breast MRI.